Detail

CHEPLAPHARM further enhances its portfolio in the Cardiology area

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

 

CHEPLAPHARM Arzneimittel GmbH is pleased to announce that we have signed definitive agreements with Bristol-Myers Squibb to acquire product SOTALEX®.

SOTALEX®/SOTACOR® (Active Ingredient: Sotalol hydrochloride) is an antiarrhythmic drug with Class II (beta-adrenoreceptor blocking) and Class III (cardiac action potential duration prolongation) actions. It is indicated for the treatment of ventricular and supraventricular arrhythmias in adults. It is unique as it has both beta-blocking and antiarrhythmic properties.

With the acquisition and sustainable integration of numerous products in the past, Cardiology already represents one of the primary therapeutic areas in CHEPLAPHARM’s portfolio.

SOTALEX®/SOTACOR® now further promotes the naturally existing synergies between the Cardiology products and, additionally, strengthens CHEPLAPHARM’s International Footprint primarily in Japan and in selected European countries.

“We are highly delighted to have reached an agreement with Bristol-Myers Squibb about the acquisition of SOTALEX®/SOTACOR®”, said CEO Sebastian F. Braun.

 

Press Office:
CHEPLAPHARM Arzneimittel GmbH | Ziegelhof 24 | 17489 Greifswald | presse(at)cheplapharm.com

Back